Though the makers of Johnson & Johnson’s Baby Powder continue to deny their responsibility for causing malignant mesothelioma, the Journal of Occupational and Environmental Medicine has just published a new study that shows that 33 individual mesothelioma patients who submitted tissue samples all tested positive for asbestos that’s found in cosmetic talc rather than in commercial asbestos products.
The report will likely be used in some of the Johnson & Johnson’s Baby Powder mesothelioma cases that are currently pending in courtrooms throughout America. The consumer giant has been accused of being aware that their product was contaminated with asbestos, and of causing both malignant mesothelioma and ovarian cancer in countless victims There are currently 15,500 cases waiting to be heard.
Juries in Johnson & Johnson’s Baby Powder Cases Have Awarded Millions to Victims
Despite the fact that there have already been several significant jury decisions awarding multi-million dollar amounts to mesothelioma plaintiffs, the makers of Johnson & Johnson’s Baby Powder continues to deny that their product causes cancer. That is what makes this new report so significant. According to Steve Gold, a professor at Rutgers Law School, “It’s very, very hard, in general, to prove exactly what caused your specific case of the disease. If a credible physician and researcher is willing to testify and has published that these individual cancers appear to be caused by asbestos exposure from talcum powder, that’s evidence that is usually not available to plaintiffs. That’s very powerful.”
In 2018, Reuters published the results of an investigation that showed that Johnson & Johnson knew that its baby powder was contaminated with asbestos but hid the information. Internal documents support this finding. These internal documents have proven to be pivotal in several of the mesothelioma cases that have been heard thus far, including a case where a California jury awarded a woman more than $29 million to compensate her for her mesothelioma diagnosis and a case where a St. Louis jury awarded 22 women $4 billion following their ovarian cancer diagnoses.